Analysts forecast that Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) will post earnings of ($0.87) per share for the current quarter, Zacks reports. Zero analysts have made estimates for Opiant Pharmaceuticals’ earnings. Opiant Pharmaceuticals reported earnings per share of ($0.52) during the same quarter last year, which suggests a negative year over year growth rate of 67.3%. The business is scheduled to report its next earnings report on Monday, October 30th.
On average, analysts expect that Opiant Pharmaceuticals will report full year earnings of $2.36 per share for the current year. For the next fiscal year, analysts anticipate that the business will report earnings of ($4.83) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that cover Opiant Pharmaceuticals.
Separately, ValuEngine lowered shares of Opiant Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, October 2nd.
Shares of Opiant Pharmaceuticals (NASDAQ OPNT) traded up 5.01% on Monday, hitting $37.75. 38,298 shares of the company’s stock were exchanged. Opiant Pharmaceuticals has a 12 month low of $5.00 and a 12 month high of $51.90. The firm has a market cap of $76.48 million, a P/E ratio of 14.20 and a beta of -0.94. The stock’s 50 day moving average is $34.43 and its 200 day moving average is $15.23.
Opiant Pharmaceuticals Company Profile
Opiant Pharmaceuticals, Inc, formerly Lightlake Therapeutics, Inc, is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Opiant Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.